The Antitumor Activity of IMGN529, a CD37-Targeting Antibody-Drug Conjugate, Is Potentiated by Rituximab in Non-Hodgkin Lymphoma Models

@inproceedings{Hicks2017TheAA,
  title={The Antitumor Activity of IMGN529, a CD37-Targeting Antibody-Drug Conjugate, Is Potentiated by Rituximab in Non-Hodgkin Lymphoma Models},
  author={Stuart W. Hicks and Katharine Crane Lai and L. Cristina Gavrilescu and Yong Yi and Surina Sikka and Prerak Shah and Meghan E. Kelly and Jenny Hyunjung Lee and Leanne Lanieri and Jose F. Ponte and Callum M. Sloss and Angela Romanelli},
  booktitle={Neoplasia},
  year={2017}
}
Naratuximab emtansine (IMGN529) is an investigational antibody-drug conjugate consisting of a CD37-targeting antibody conjugated to the maytansine-derived microtuble disruptor, DM1. IMGN529 has shown promising preclinical and clinical activity in non-Hodgkin lymphoma, including diffuse large B-cell lymphoma (DLBCL). Due to the aggressive nature of the… CONTINUE READING